Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
61 results about "Invariant natural killer T-cell" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Natural killer T cells can share other features with NK cells, as well, such as CD16 and CD56 expression and granzyme production. Invariant natural killer T (iNKT) cells express high levels of and are dependent on the transcriptional regulator promyelocytic leukemia zinc finger for their development.
Genetically modified human natural killer cell lines
ActiveUS8313943B2Increase rangeHelp studyDrug screeningImmunoglobulins against cell receptors/antigens/surface-determinantsFc(alpha) receptorFc receptor
The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
Owner:INST FOR CANCER RES
Mammalian common lymphoid progenitor cell
A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for lymphoid lineages, but lacking the potential to differentiate into myeloid and erythroid lineages. Methods are provided for the isolation and culture of this common lymphoid progenitor cell (CLP). The cell enrichment methods employ reagents that specifically recognize CDw127 (IL-7 receptor α); CD117 (c-kit) protein, in conjunction with other markers expressed on lineage committed cells. The murine cells are also characterized as expressing low levels of sca-1 (Ly-6E and Ly-6A). The CLPs are predominantly cycling, blast cells. These cells give rise to B cells, T cells and natural killer cells, as evidenced by their growth and differentiation in vitro and in vivo.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells
ActiveUS20150152387A1Improve efficiencyImprove efficacyBiocideMammal material medical ingredientsNatural Killer Cell FunctionNatural killer cell
The present invention relates to a method for inducing and expanding natural killer cells derived from peripheral blood mononuclear cells, which comprises co-culturing, as feeder cells, irradiated Jurkat cells and irradiated Epstein-Barr virus transformed lymphocyte continuous line (EBV-LCL) cells in the presence of cytokines, along with peripheral blood mononuclear cells. According to the present invention, a large quantity of natural killer cells can be induced and proliferated from a small quantity of peripheral blood mononuclear cells even without the use of high-cost equipment or various kinds of expensive cytokines, thereby making it possible to significantly improve the efficiency and efficacy of the prevention and treatment of cancer using the natural killer cells.
Owner:NKMAX CO LTD
Glycosphingolipids for use in modulating immune responses
ActiveUS20140377291A1Modulate immune responseEnhance immune responseAntibacterial agentsBiocideAutoimmune diseaseSphingolipid metabolism
Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer T cells. The compounds are therefore useful for treating or reducing the likelihood of occurrence of an immune diseases and disorders, such as autoimmune diseases or disorders. The compounds may also be used for treating or reducing the likelihood of occurrence of a microbial infection or for treating or reducing the likelihood of occurrence of a cancer in a subject by administering the sphingolipid compounds described herein.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +1
Modified alpha-galactosyl ceramides for staining and stimulating natural killer t cells
InactiveUS20090047299A1Improve solubilityEasy loadingAntibacterial agentsBiocideNatural killer cellInvariant natural killer T-cell
Modified glycolipid compounds are provided. Also disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, and methods suitable for labeling NKT cells.
Owner:BRIGHAM YOUNG UNIV +2
Artificial antigen presenting cell and application thereof in NK (natural killer) cell amplification
InactiveCN102559600AHigh purityStrong cytotoxicityBlood/immune system cellsRecombinant DNA-technologyNatural Killer Cell Inhibitory Receptors4-1BB ligand
The invention provides an in vitro amplification method for efficient and highly cytotoxic natural killer (NK) cells. Novel artificial antigen presenting cells 4-1BBL-mIL-21-aAPC, such as 4-1BBL-mIL-21-K562 cells and the like, are constructed through stably expressing 4-1BB ligands (4-1BBL) and membrane immobilized interleukin 21 (mIL-21) on the surfaces of cell membranes, and by using the novel artificial antigen presenting cells as feeder cells for amplification, the NK cells are directly amplified from peripheral blood lymphocytes. Flow cytometry, cytotoxicity test and the like suggest that the amplified cells NK have high purity and strong cytotoxicity and have obvious killing effect on tumor cells.
Owner:SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
Method for jointly preparing CAR-NK (chimeric antigen receptor-natural killer) cells and CAR-NKT (natural killer T) cells
ActiveCN106350487AReduce purification costsEfficient killingBlood/immune system cellsCell culture active agentsPeripheral blood mononuclear cellNatural Killer Cell Inhibitory Receptors
The invention discloses a method for jointly preparing CAR-NK (chimeric antigen receptor-natural killer) cells and CAR-NKT (natural killer T) cells. The method includes steps of 1), adding peripheral blood mononuclear cells into cell culture media, pre-activating NK cells and NKT cells in the peripheral blood mononuclear cells and selectively activating and amplifying the NK cells and the NKT cells in an in-vitro manner; 2), transducing mixed cells obtained at the step 1) by the aid of lentiviral vectors with gene sequences of chimeric antigen receptors. The method has the advantages that the CAR-NK cells and the CAR-NKT cells can be prepared from NKs and NKTs of healthy donors in a standardized and batched manner; the purity of the NK cells and the NKT cells can respectively reach 60% and 30% at least without purification, and accordingly preliminary purification can be omitted; the in-vivo activation and amplification degrees and the in-vivo existence time of the CAR-NK cells and the CAR-NKT cells which are jointly prepared by the aid of the method can be controlled by means of clinical medication.
Owner:BEIJING DOINGTIMES INST OF TRANSLATIONAL MEDICINE
Growth method for natural killer cells
The present invention relates to an improved growth method for natural killer cells (NK cells). More specifically, the present invention relates to a growth method for natural killer cells, which comprises a step of culturing natural killer cells in a medium containing anti-CD3 antibodies and interleukin proteins in the presence of peripheral blood leukocytes. The present invention provides an innovative growth method for natural killer cells, which can obtain a large amount of natural killer cells by remarkably increasing the growth rate compared with conventional growth methods for natural killer cells.
Owner:GREEN CROSS LAB CELL CORP +1
Methods and compositions for natural killer cells
ActiveUS9623082B2Reduce in quantityIncrease the number ofPeptide/protein ingredientsCulture processNatural killer cellWilms' tumor
The application provides new compositions and methods for stimulating the production of natural killer (NK) cells in a subject. NK cells can be selectively expanded with a combination of stimulating ligands. Methods and compositions for the administration of stimulatory ligands modified to self-insert into tumor cells, thereby stimulating an increase in the number of NK cells in proximity to a tumor, are also described.
Owner:UNIV OF CENT FLORIDA RES FOUND INC
Natural killer cell lines and methods of use
InactiveUS20140099714A1Peptide/protein ingredientsGenetically modified cellsCancer cellWhite blood cell
This invention relates to a natural killer cell line termed NK-92. The invention provides a vector for transfecting a mammalian cell which includes a nucleic acid sequence encoding a cytokine that promotes the growth of NK-92. Additionally, the invention provides an NK-92 cell, or an NK-92 cell modified by transfection with a vector conferring advantageous properties, which is unable to proliferate and which preserves effective cytotoxic activity. The invention further provides a modified NK-92 cell that is transfected with a vector encoding a cytokine that promotes the growth of NK-92 cells. The cell secretes the cytokine upon being cultured under conditions that promote cytokine secretion, and furthermore secretes the cytokine in vivo upon being introduced into a mammal. In a significant embodiment, the cytokine is interleukin 2. The present invention also provides methods of purging cancer cells from a biological sample, of treating a cancer ex vivo in a mammal, and of treating a cancer in vivo in a mammal employing a natural killer cell, such as NK-92 itself, an NK-92 cell which is unable to proliferate and which preserves effective cytotoxic activity, or natural killer cells transfected with a vector encoding a cytokine.
Owner:CONKWEST
Method for amplifying natural killer t cells
InactiveUS20040009594A1Potent activityEffective in vitro expansionMammal material medical ingredientsArtificial cell constructsCell FractionG-csf therapy
Human Valpha24<+> natural killer T cells are expanded by culturing a mononuclear cell fraction obtainable from human peripheral blood in which hemopoietic stem cells are mobilized by granulocyte colony-stimulating factor, in the presence of a cytokine, such as interleukin 2, effecting proliferation and / or activation of lymphocytes and alpha-glycosylceramide. A cell fraction comprising human Valpha24<+> natural killer T cells expanded by the method, is useful as a cancer-treating agent.
Owner:KIRIN BREWERY CO LTD
Preparation method and application of bispecific antibody targeting CD24 (cluster of differentiation 24) and activating NK cells (natural killer cells)
InactiveCN109678963AAvoid immune escapeEnhanced ADCC effectHybrid immunoglobulinsDigestive systemImmunocompetenceNatural Killer Cell Inhibitory Receptors
The invention belongs to the technical field of genetic engineering antibodies, and particularly relates to a preparation and application of a bispecific antibody targeting a CD24 (cluster of differentiation 24) and activating NK cells (natural killer cells). According to the preparation and application of the bispecific antibody, an anti-CD24 humanized chimeric antibody cG7 and an MICA molecule capable of recruiting and activating the activity of the NK cells are connected through flexible peptide (Gly4Ser) and are stably transferred to a CHO-s eukaryotic expression system, and a stable high-expression cell strain is selected for propagation and expression of cG7-MICA; the bispecific antibody cG7-MICA utilizes the function of remodeling the MICA by utilizing the targeting effect of the cG7 to selectively display the MICA on the surface of a CD24+ tumor cell, the immune surveillance effect of the NK cells is induced, in addition, the NK cells are further activated through the effect ofan Fc part, and the antibody-dependent cell-mediated cytotoxicity (ADCC) is achieved; and through experimental verification, the immunocompetence of killing the CD24+ hepatocellular carcinoma cells is achieved in vitro and vivo.
Owner:CHINA PHARM UNIV
Vaccine comprising monocyte or immature myeloid cells (IMC) which were loaded with the ligand of natural killer T cell and antigen
ActiveUS9518126B2Improve isolationInduce immune responseAntibacterial agentsAntiviralsAbnormal tissue growthDendritic cell
The present invention relates to an immuno-therapeutic and prophylactic vaccine comprising monocytes or immature myeloid cells (IMCs) loaded with the ligand of natural killer T cell and an antigen for the prevention and treatment of infectious disease or cancer, more precisely, an immuno-therapeutic and prophylactic vaccine comprising monocytes or IMCs loaded with α-galactosylceramide (αGalCer), a kind of glycolipid and a natural killer T cell ligand, and antigen. Monocytes or immature myeloid cells (IMCs) therein, which are easily obtainable, unlike dendritic cells, not only induce a significant level of cytotoxic T lymphocyte responses but also have a prophylactic and therapeutic effect on malignant tumor. Therefore, the immuno-therapeutic and prophylactic vaccine of the present invention can be effectively used as an immunotherapeutic agent.
Owner:CELLID
Modified natural killer cells and natural killer cell lines having increased cytotoxicity
ActiveUS20170157230A1High cytotoxic activityGenetically modified cellsBoron compound active ingredientsNatural Killer Cell Inhibitory ReceptorsNatural killer cell
NK cells and NK cell lines are modified to increase cytotoxicity, wherein the cells and compositions thereof have a use in the treatment of cancer. Production of modified NK cells and NK cell lines is via genetic modification to remove checkpoint inhibitory receptor expression and / or add mutant (variant) TRAIL ligand expression.
Owner:ONK THERAPEUTICS LTD
Invariant natural killer T (iNKT) cell expressing targeted GPC3 chimeric antigen receptor and preparation and application for invariable natural killer T (iNKT) cell
ActiveCN107384949AImmunoglobulins against cell receptors/antigens/surface-determinantsMammal material medical ingredientsSingle-Chain AntibodiesHinge region
The invention discloses an invariant natural killer T (iNKT) cell expressing a targeted GPC3 chimeric antigen receptor and preparation and application for the iNKT cell. The chimeric antigen receptor contains a hinge region, a transmembrane region and an intracellular signal region of a single chain antibody GPC3-ScFv, CD8 which recognize a C tail end epitope of GPC3, wherein the hinge region, the transmembrane region and the intracellular signal region are connected according to series structure domains. Preparation of the iNKT cell modified by the chimeric antigen receptor comprises the following steps that a chimeric antigen receptor pRRL-gc33-28BBz is built, and the iNKT cell is infected; and after special amplification in vitro, the GPC3-targetted iNKT cell is obtained. According to the iNKT cell expressing the targeted GPC3 chimeric antigen receptor and preparation and application for the iNKT cell, the nucleic acids encoding the chimeric antigen receptor protein, a plasmid containing the nucleic acids, a virus containing the plasmid and the transgenic iNKT lymphocyte transduced by the virus can be effectively applied to tumor immunotherapy.
Owner:BEIJING GENE KEY LIFE TECH CO LTD
Preparation method for monkshood polysaccharide-induced nature killer T (NKT) cell proliferation and application thereof
The invention provides a culture method for monkshood polysaccharide-induced nature killer T cell (Nature Killer T cell, NKT) proliferation. The method comprises the characteristics as follows: human peripheral blood, marrow or a mononuclear cell with an umbilical cord blood source are continuously cultivated by traditional Chinese medicine monkshood polysaccharide and recombinant human interleukin 2, a lot of nature kill T cells are obtained, NK<1.1+> and CD<8+> are expressed, interferon gamma is secreted, the ratio in lymphocyte at the 14th day is more than 16.15%, the order of magnitude can be up to over 5*10<9>, and the nature kill T cell have effective anti-tumor and anti-virus functions. A clinical application of the NKT cell obtained by the method is also provided by the invention.
Owner:李金珍
Fusion protein for NKT (natural killer T) cell culture, encoding gene and application
InactiveCN106810612AEnhance tumor killing activityPromote proliferationConnective tissue peptidesAntibody mimetics/scaffoldsPeripheral blood mononuclear cellLymphocyte
The invention relates to the field of biotechnology and medical science, in particular to a fusion protein for NKT (natural killer T) cell culture, an encoding gene and an application. The fusion protein is used for preparing NKT cells which are high in proliferating activity and killing activity. The fusion protein ICAM1-FN (intercellular adhesion molecule-1-fibronectin) can effectively stimulate proliferation of lymphocytes in the culture process of the NKT cells, the proportion of CD3 / CD56 double-positive cells is improved, so that the in-vitro amplification efficiency of peripheral blood mononuclear cells is twice that of a traditional method, the proportion of CD3 / CD56 double-positive cells is 2-10 times that of the traditional method, tumor killing activity of the NKT cells is enhanced, and the tumor killing activity of the prepared method of the NKT cells is improved by 15%-35% as compared with the traditional method.
Owner:深圳市艾克希尔生物科技有限公司
Natural killer T cell culture medium and multiplication culture method for natural killer T cells
ActiveCN107488630AHigh activityPromote proliferationCulture processCell culture supports/coatingHeterologousSerum free media
The invention provides a natural killer T cell culture medium and a multiplication culture method for natural killer T cells and relates to the technical field of cell culture. The natural killer T cell culture medium, disclosed by the invention, is mainly composed of a serum-free medium, autologous plasma and a cell factor IL-2. According to the multiplication culture method for natural killer T cells by using the cell culture medium, human-derived peripheral blood mononuclear cells are induced to release a danger signal by virtue of the antibody binding cell factor IL-2, and further the natural killer T cells are activated. According to the method, high-quality natural killer T cells can be obtained by massive high-efficiency multiplication in a short period on premise of ensuring the security. The potential security risk caused by culture of heterogenous animal serum or tumor cells in the conventional natural killer T cell culture method and the problems that the conventional natural killer T cell culture method is low in multiplication times and low in purity and is difficult to use on a large scale are effectively solved.
Owner:TIANJIN CHANGHE BIOLOGICAL TECH
Vaccine comprising monocyte or immature myeloid cells (IMC) which were loaded with the ligand of natural killer t cell and antigen
ActiveUS20090285851A1Improve isolationInduce immune responseAntibacterial agentsOrganic active ingredientsDendritic cellImmunotherapeutic agent
The present invention relates to an immuno-therapeutic and prophylactic vaccine comprising monocytes or immature myeloid cells (IMCs) loaded with the ligand of natural killer T cell and an antigen for the prevention and treatment of infectious disease or cancer, more precisely, an immuno-therapeutic and prophylactic vaccine comprising monocytes or IMCs loaded with α-galactosylceramide (αGalCer), a kind of glycolipid and a natural killer T cell ligand, and antigen. Monocytes or immature myeloid cells (IMCs) therein, which are easily obtainable, unlike dendritic cells, not only induce a significant level of cytotoxic T lymphocyte responses but also have a prophylactic and therapeutic effect on malignant tumor. Therefore, the immuno-therapeutic and prophylactic vaccine of the present invention can be effectively used as an immunotherapeutic agent.
Owner:CELLID
Method of amplifying natural killer T cells
InactiveCN1444648AMammal material medical ingredientsCancer antigen ingredientsLymphocyte proliferationNatural killer cell
Expansion of human Vα24+ natural killer T by culturing a monocyte fraction obtainable from human peripheral blood in the presence of a cytokine capable of proliferating and / or activating lymphocytes and α-glycosylceramide cells, the hematopoietic stem cells in the peripheral blood are mobilized by granulocyte-colony stimulating factor. The cell fraction containing human Vα24+ natural killer T cells expanded by this method can be used as an effective cancer therapeutic agent.
Owner:KIRIN BREWERY CO LTD
Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells
ActiveUS9938498B2Improve efficacyImprove efficiencyMammal material medical ingredientsBlood/immune system cellsNatural Killer Cell FunctionNatural killer cell
The present invention relates to a method for inducing and expanding natural killer cells derived from peripheral blood mononuclear cells, which comprises co-culturing, as feeder cells, irradiated Jurkat cells and irradiated Epstein-Barr virus transformed lymphocyte continuous line (EBV-LCL) cells in the presence of cytokines, along with peripheral blood mononuclear cells. According to the present invention, a large quantity of natural killer cells can be induced and proliferated from a small quantity of peripheral blood mononuclear cells even without the use of high-cost equipment or various kinds of expensive cytokines, thereby making it possible to significantly improve the efficiency and efficacy of the prevention and treatment of cancer using the natural killer cells.
Owner:NKMAX CO LTD
Method for efficient in-vitro amplification and culture of natural killer T cells with high killing capacity
PendingCN110283786AEasy to obtainHigh Effector Cell PurityMammal material medical ingredientsBlood/immune system cellsAbnormal tissue growthSide effect
The invention discloses a method for efficient in-vitro amplification and culture of natural killer T cells with high killing capacity. The method comprises the following steps: a, taking fresh human peripheral blood and obtaining mononuclear cells with a gradient centrifugation method; b, pre-stimulating mononuclear cells in an in vitro medium; c, expanding culture of peripheral blood derived mononuclear cells, detecting the proportion of various cells, and judging amplification efficiency and activity of the target NK / NKT cells; d, detecting the proportion of NK / NKT cells to the cell population after culture for 3-4 weeks, and detecting cell killing efficiency; e, further purifying the NK / NKT cells. The method is simple to operate, the NK cell population rich in NKT cells with high killing activity is obtained and contains no impurity cells, immunogenicity caused by the impurity cells is avoided, and side effects in clinical application are lower. Besides, the method has the advantages that materials are easily available, the cells are suitable for large-scale culture, damage to the body is small and the like, and is more suitable for adjuvant treatment of tumor patients.
Owner:INST OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINESE ACADEMY OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE
Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
ActiveCN101878034AMammal material medical ingredientsBlood/immune system cellsAbnormal tissue growthCancer cell
Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer (PINK) cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. In a preferred embodiment, the composition comprises: solated CD56+, CD16- natural killer cells.
Owner:ANTHROGENESIS LLC
In vivo priming of natural killer cells
ActiveUS20170071982A1Promoting tumor cell lysisImmunoglobulin superfamilyEnergy modified materialsLysisCD16
The disclosure concerns a method for cancer treatment by in vivo priming and activation of natural killer cells for achieving tumor cell lysis. The method includes introducing into a patient a priming tumor cell preparation (PTCP) derived from a first tumor cell line, which is irradiated to inactivate the first tumor cells or a membrane preparation thereof, the first tumor cells having known priming ligands on the membrane surface thereof. The patient's rest NK cells are contacted by the PTCP in vivo, resulting in primed NK cells, which are characterized by upregulation of CD69, shedding of CD16, or a combination of CD69+ and CD16−. These primed NK cells then contact second tumor cells, the cancer, and are configured to lyse and kill the second tumor cells.
Owner:IMMUNE VENTURES LLC
Method of using cd1d over-expression in human dendritic cells to enhance cd8+ t cell-based and invariant natural killer t cell-based antitumor immunity
InactiveUS20130344095A1Genetically modified cellsSnake antigen ingredientsAntitumor immunityDendritic cell
The manipulation of human dendritic cells (DCs) to induce potent anti-tumor immunity remains an essential subject of study. Here we report that the overexpression of CD1d in human DCs can enhance the priming of naïve CD8+ T cells against tumor antigen. We showed that CD1d can be overexpressed in the human DCs using baculoviral vector carrying the CD1d gene. This CD1d-overexpression is functional as demonstrated by the increased expansion of invariant natural killer T (iNKT) cells while using these modified DCs to present α-galactosylceramide (α-GC). Pulsed with tumor antigenic peptide, these CD1d-overexpressing human DCs showed enhanced capability to prime naïve CD8+ T cells. CD1d-overexpressing human DCs also induced a pro-inflammatory cytokine profile that may favor the priming. Moreover, this CD1d-overexpression strategy can be extrapolated to monocyte-derived human DCs. Therefore, our study suggest that overexpression of CD1d in human DCs may provide a novel strategy to enhance DC immunogenicity and the possible translation into human cancer immunotherapy.
Owner:AGENCY FOR SCI TECH & RES
Modified α-galactosyl ceramides for staining and stimulating natural killer T cells
InactiveUS8227581B2Easy loadingStimulate NKT cells more effectivelyAntibacterial agentsBiocideStainingGlycolipid
Modified glycolipid compounds are provided. Also disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, and methods suitable for labeling NKT cells.
Owner:BRIGHAM YOUNG UNIV +2
Functionality detection and evaluation method and functionality detection kit for liver disease NK (natural killer) cells
ActiveCN108663510ACheck overall functionalityMaterial analysisNatural Killer Cell Inhibitory ReceptorsOrganism
Owner:PRESEE BIOTECH CO LTD
Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
ActiveCN103356702AMammal material medical ingredientsBlood/immune system cellsAbnormal tissue growthCancer cell
Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer (PINK) cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. In a preferred embodiment, the composition comprises: solated CD56+, CD16- natural killer cells.
Owner:ANTHROGENESIS LLC
Targeting the tumor microenvironment using manipulated nkt cells
InactiveUS20210220403A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigenAntigen receptors
Owner:BAYLOR COLLEGE OF MEDICINE
Targeting the tumor microenvironment using manipulated nkt cells
InactiveUS20210106622A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigenAntigen receptors
Owner:BAYLOR COLLEGE OF MEDICINE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com